Diagnosis and potential treatment of antiphospholipid syndrome-related mainly on ischemic stroke

Brain and Nerve

Volumn 65, Issue 11, 2013, Pages 1319-1332

  Okuma, Hirohisa ^a   Kitagawa, Yasuhisa ^a  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

Author keywords

Anti 2 glycoprotein I antibody; Antiphospholipid syndrome; Ischemic stroke; Lupus anticoagulant; Phosphatidylserine dependent anti prothrombin antibody

Indexed keywords

APIXABAN; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; DABIGATRAN; HEPARIN; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PROTHROMBIN ANTIBODY; RIVAROXABAN; STEROID;

ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PLASMAPHERESIS; PRACTICE GUIDELINE; TRANSIENT ISCHEMIC ATTACK;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINES AS TOPIC; STROKE;

EID: 84888066765     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Rodrigues CE, Carvalho JF, Shoenfield Y: Neurological manifestations of Antiphospholipid syndrome. Eur J Clin Invest 40: 350-359, 2010
2. Bowie EJ, Thompson JH Jr, Pascuzzi CA, Owen CA Jr: Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62: 416-430, 1963
3. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, et al: Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2: 1211-1214, 1983
4. Hughes GRV: The anticardiolipin syndrome. Clin Exp Rheumatol 3: 285-286, 1985
5. Brain Nerve 60: 1144-1158, 2008
6. Atsumi T, Leco M, Bertolaccini ML, Ichikawa K, Tsutsumi A, et al: Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43: 1982-1993, 2000
7. Miyakisu S, Lockshin MD, Atsumi T, Branch DW, Brey RL, et al: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306, 2006
8. Sciascia S, Lopez-Pedrera C, Roccatello D, Cuadrado MJ: Catastrophic antiphospholipid syndrome (CAPS). Best Pract Res Rheumatol 26: 535-541, 2012
9. Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, et al: Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol 59: 227-230, 1985
10. Levine SR, Brey RL, Tliiey BC, Thompson JL, Sacco RL, et al: Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291: 576-584, 2004
11. Cervera R, Boffa MC, Khamashta MA, Hughes GR: The Euro-phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 18: 889-893, 2009
12. Liestol S, Sandset P, Mowinckel MC, Wisloff F: Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost 5: 2204-2210, 2007
13. Comp PC, De Bault LE, Esmon NL, Esmon CT: Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants. Blood 62(suppl): 299a, 1983
14. Cariou R, Tobelem G, Soria C, Caen J: Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 314: 1193-1194, 1986
15. De Groot PG, Meijers JCM, Urbanus RT: Recent developments in our understanding of the antiphospholipid syndrome. Int Jnl Lab Hem 34: 223-231, 2012
16. Abdel-Monen H, Daguputa SK, Le A, Prakasam A, Thiagarajan P: Phagocytosis of platelet microvesicles and beta2-glycoprotein I. Thrombosis and Haemostasis 104: 335-341, 2010
17. Agar C, van Os GM, Mörgelin M, Sprenger RR, Marquart JA, et al: Beta2-Glycoprotein I can exist in two conformations; implications for our understanding of the antiphospholipid syndrome. Blood 116: 1336-1343, 2010
18. Kitagawa Y, Gotoh F, Koto A, Okayasu H: Stroke in systemic lupus erythematosus. Stroke 21: 1533-1539, 1990
19. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, et al: Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 98: 815-825, 1996
20. Matuura E, Koike T: Accelerated atheroma and anti-β2-glycoprotein I antibodies. Lupus 9: 210-216, 2000
21. George J, Afek A, Gilburd B, Harats D, Shoenfeld Y: Autoimmunity in atherosclerosis: lessons from experimental models. Lupus 9: 223-227, 2000
22. Lambriancides A, Carroll C, Pierangeli S, Pericleous C, Branch W, et al: Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte sinalling pathways. J Immunol 184: 6622-6628, 2010
23. Vega-Ostertag M, Ferrara D, Romay-Penabad Z, Liu X, Taylor WR, et al: Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 5: 1828-1834, 2007
24. Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, et al: The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2- glycoprotein I antibodies. Int Immunol 16: 1633-1641, 2004
25. Girardi G, Redecha P, Salmon JE: Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nab Med 10: 1222-1226, 2004
26. Harper BE, Willis R, Pierangeli SS: Pathophysiological mechanisms in antiphospholipid syndrome. Int J Clin Rhematol 6: 157-171, 2011
27. Rand JH, Wu XX, Quinn AS, Taatjes DJ: Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 17: 922-930, 2008
28. Alessandri C, Conti F, Pendulino M, Mancini R, Valesini G: New autoantigens in the antiphospholipid syndrome. Autoimmunity Reviews 10: 609-616, 2011
29. Sakai Y, Atsumi T, Leko M, Amengual O, Furukawa S, et al: The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum 60: 2457-2467, 2009
30. Yang Yh, Chang CJ, Chuang YH, Hsu HY, Chen PP, et al: Identification of antiprothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity. Rheumatology 49: 34-42, 2010
31. Vega-Ostertag M, Liu X, Kwan-Ki H, Chen P, Pierangeli A: A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 135: 214-219, 2006
32. Lopez-Sato A, Cervera R, Front J, Bove A, Reverter JC, et al: Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. Clin Exp Rheumatol 15: 143-149, 1997
33. Okuma H, Kitagawa Y, Takagi S: Investigation of antiphosphatidyl-serine antibody and antiphosphatidyl-inositol antibody in ischemic stroke patients. Clin Dev Immunol 1155: 1-4, 2010
34. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, et al: Thrombosis, recurrent fetal loss, and thrombocytopnenia: predictive value of the anticardiolipin antibody test. Arch Intern Med 146: 2153-2156, 1986
35. Tripodi A, De Groot PG, Pengo V: Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 270: 110-122, 2011
36. Willis R, Harris NE, Pierangeli SS: Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 38: 305-321, 2012
37. Rahgozar S: Revisiting beta 2 glycoprotein I, the major autoantigen in the antiphospholipid syndrome. Iran J Immunol 9: 73-85, 2012
38. Chamorro AJ, Marcos M, Miro'n-Canelo JA, Cervera R, Espinosa G: Val 2471eu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis. Autoimmunity Reviews 11: 705-712, 2012
39. Emmanuel J, Richard CW: The antiphospholipid syndrome: Diagnosis, pathogenesis, laboratory testing, and management. Semin Thromb Hemost 38: 299-304, 2012
40. Atsumi T, Amenqual O, Yasuda S, Koike T: Antiprothrombin antibodies: are they worth assaying? Thromb Res 114: 533-538, 2004
41. Okuma H, Kitagawa Y, Ishikawa T, Takagi S: Study of phosphatidylserine- dependent anti-prothrombin antibody in cerebral infarction. Intern Med 48: 1351-1355, 2009
42. Harris EN, Gharavi AE, Asherson RA, Boey ML, Hughes GR: Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 2: 47-51, 1984
43. Levine SR, Welch KMA: Cerebrovascular ischemia associated with lupus anticoagulant. Stroke 23: 257-263, 1987
44. Feldmann E, Levine SR: Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms,significance,and therapeutic options. Ann Neurol 37: 114-130, 1995
45. Stefan H, Bauer J, Feistel H, Schulemann H, Neubauer U, et al: Regional cerebral blood flow during focal seizure of temporal and frontocentral onset. Ann Neurol 27: 162-164, 1990
46. Asherson RA, Espinosa G, Menahem S, Menahaem S, Yinh J, et al: Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 37: 366-372, 2008
47. Cervera R: 8th international congress on autoimmunity: new perspectives for refractory catastrophic antiphospholipid syndrome. Expert Rev Clin Immunol 8: 617-619, 2012
48. Cervera R, Espinosa G: Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". Semin Thromb Hemost 38: 333-338, 2012
49. Provenzale JM, Barboriak DP, Allen NB, Allen NB, Ortel TL: Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am J Roentgenol 167: 1573-1578, 1996
50. Chen WH, Lin HS, Kao YF, Liu JS: Delayed catastrophic antiphospholipid syndrome after massive cerebral infarction. Neurocrit Care 7: 148-151, 2007
51. 7: 124-125, 2008
52. Jonas J, Kölble K, Völcker HE, Kalden JR: Central retinal artery occlusion Sneddon's disease associated with antiphospholipid syndrome. Am J Ophthal 102: 37, 1986
53. Church RE: Reticular livedo with cerebro-vascular lesions. Br J Dermatol 74: 156-157, 1962
54. Campion RH, Rook A: Livedo reticularis. Proc R Soc Med 53: 961-962, 1960
55. Sneddon IB: Cerebro-vascular lesions and livedo reticuraris. Br J Dermatol 77: 180-185, 1965
56. Bolari E, Yilmaz A, Kugu N, Erdoqan H, Akyol M, et al: Sneddon's syndrome: clinical and laboratory analysis of 10 cases. Acta Medica Okayama 58: 59-65, 2004
57. Greaves M, Cohen H, MacHin SJ, Mackie I: Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109: 704-715, 2000
58. Jacobs BS, Levine SR: Antiphospholipid antibody syndrome. Cure Treat Options Neurol 2: 449-458, 2000
59. Rosove MH, Brewer PMC: Antiphosopholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117: 303-308, 1992
60. Khamashta MA, Cuadrado MJ, Mujic E, Taub NA, Hunt BJ, et al: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332: 993-997, 1995
61. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, et al: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349: 1133-1138, 2003
62. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, et al: A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy antiphospholipid syndrome (WAPS). J Thromb Haemos 3: 848-853, 2005
63. Wittkowsky AK, Downing J, Blackburn J, Nutescu E: Warfarine-related outcome in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 96: 137-141, 2006
64. Derksen RH, de Groot PG, Kappelle LJ: Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology 61: 111-114, 2003
65. Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S: Comparison between single antiplatelet therapy for and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke. Int J Med Sci 7: 15-18, 2009
66. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al: Dabigatran versous warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151, 2009
67. Hurley D: FDA approval sought for rivaroxaban to prevent stroke in atrial fibrillation. Neurology Today 11: 22-23, 2011
68. Ahrens I, Lip GY, Peter K: What do the RE-LY, AVERROES and ROCKET-AF traials tell us or stroke prevention in atrial fibrillation? Thromb Haemost 105: 574-578, 2011
69. Connolly SJ, Eikelboom J, Joyner C, Eikelboom J, Oldqren J, et al: Apixaban in patients with atrial fibrilaation. N Engl J Med 364: 806-817, 2011
70. Pierangeli SS, Erkan D: Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 19: 475-485, 2010
71. Kumar D, Roubey RA: Use of rituximab in the antiphospholipid syndrome. Curr Rheumatol Rep 12: 40-44, 2010
72. Brey RL: New treatment option for the antiphospholipid antibody syndrome?: more pleiotropic effects of the statin drugs. J Thromb Haemost 2: 1556-1557, 2004
73. Panichpisal K, Rozner E, Levine SR: The management of stroke in antiphospholipid syndrome. Curr Rheumatol Rep 14: 99-106, 2012
74. Amengual O, Atsumi T, Koike T: Pathophysiology of thrombosis and potential targeted therapies in antiphospholipid syndrome. Curr Vas Pharma 9: 606-618, 2011